Spero Therapeutics’ (SPRO) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

SPRO has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. Evercore ISI lowered shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target for the company. in a research report on Friday, December 20th. Finally, TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

Spero Therapeutics Stock Performance

Shares of SPRO stock opened at $0.87 on Thursday. Spero Therapeutics has a 52-week low of $0.83 and a 52-week high of $1.89. The company has a 50-day simple moving average of $1.02 and a two-hundred day simple moving average of $1.21. The company has a market capitalization of $47.43 million, a price-to-earnings ratio of 12.43 and a beta of 0.63.

Hedge Funds Weigh In On Spero Therapeutics

A hedge fund recently raised its stake in Spero Therapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 975,952 shares of the company’s stock after buying an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned about 1.81% of Spero Therapeutics worth $1,269,000 at the end of the most recent quarter. 25.60% of the stock is owned by hedge funds and other institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.